LifeVantage (LFVN) investor relations material

Company overview and business model

• Operates in activation and nutrigenomics, offering science-based natural products through a direct sales model with 50,000 consultants and 132,000 customers in 20 countries.

• 70% of revenue is subscription-based, with most products sold in 30-day packs and a high variable cost structure.

• Fiscal 2025 revenue reached $229 million with $22 million EBITDA, and a market cap of $167 million.

• 79% of revenue comes from North America, with growth opportunities identified in Europe and Asia.

• Recently announced the acquisition of LoveBiome, focused on gut health, expected to close and integrate by November 1.

Product innovation and clinical results

• Four hero products drive the portfolio, with Protandim Nrf2 as the flagship, representing nearly 50% of revenue.

• MindBody GLP-1, a natural alternative to synthetics, showed a 200% increase in GLP-1 production and average 11 lbs weight loss over 12 weeks in clinical studies.

• Clinical results include 9% decrease in body fat, 24% decrease in visceral fat, 6% increase in skeletal muscle, and no muscle loss.

• LoveBiome’s P84 product targets gut microbiome health with a holistic approach, supporting the bundling strategy for synergistic benefits.

• Product stacking and bundling are emphasized to maximize health benefits and customer value.

Financial performance and capital allocation

• Gross margin improved above 80% in FY 2025, with EBITDA margin rising to just under 10% and a long-term target of 12%.

• FY 2025 revenue grew over 14% year-over-year, driven by the MindBody product launch.

• U.S. revenue increased by over 20% year-over-year, with Japan as the second largest market at 11%.

• Maintains a strong balance sheet with $20 million in cash, $24 million in working capital, and access to a $5 million credit facility and $75 million shelf registration.

• Capital allocation includes internal investment, a quarterly dividend (increased annually for three years), a special dividend, and an active $60 million share repurchase program.